Active Government Funding Opportunities

This DOD program funds translational trauma care research that moves promising medical technologies from concept toward real-world solutions. Projects must demonstrate preliminary data and advance casualty survivability and point-of-injury care.

Supports investigator-initiated research advancing bone marrow failure treatments through translational and clinical studies. Funds mature ideas with IND-enabling efforts and correlative research to drive significant patient care improvements.

Seeking early-stage research to develop novel therapies for Duchenne muscular dystrophy across all age groups, from infants to nonambulatory individuals. High-risk/high-reward studies with strong preliminary data that could accelerate near-term clinical outcomes.

The Army seeks patient-centered research to advance burn treatment and recovery outcomes for military personnel. This funding supports innovative clinical studies and therapeutic approaches to improve care for burn-injured soldiers.

The Army seeks innovative technologies and therapeutic approaches to treat severe burn injuries in military personnel. This award funds development of novel burn treatment solutions from basic research through clinical application.

NASA seeks visionary advanced concepts to push the boundaries of space exploration and technology. Phase II awards fund up to two years of development for promising innovations with potential infusion across NASA and beyond.

Support early-career scientists conducting dissertation research on Arctic environmental and social systems change. Funding advances fundamental understanding of rapid Arctic transformation and builds STEM workforce capacity in polar sciences.

DoD seeks applied medical research that translates basic science into near-term clinical solutions for military health problems. Fund up to $3.6M over 4 years for use-inspired research addressing congressionally directed priority topics.

This pilot award funds innovative ovarian cancer research that challenges current thinking and explores novel concepts to drive breakthrough discoveries. Projects must demonstrate exceptional scientific merit and innovative approaches to advance the field.

Support early-career ovarian cancer researchers through an intensive virtual academy offering mentoring, networking, and collaboration. The program develops productive scientists while advancing innovative ovarian cancer research in a structured peer-learning environment.

High-risk, high-reward medical research discovery projects addressing critical DoD health challenges. Pioneering studies generating preliminary data to launch future scientific investigation and product development.

Support early-career clinical trialists developing new ovarian cancer treatments through intensive mentoring, networking, and conducting translational research and early-phase clinical trials.

DoD funds breakthrough breast cancer research advancing toward clinical trials, requiring multidisciplinary teams with consumer advocates. This Level 4 award targets high-impact discoveries ready for human testing and clinical application.

This award funds clinical trials for new ovarian cancer treatments, from early proof-of-concept studies through large-scale efficacy trials. It supports evaluation of drugs, biologics, devices, and emerging technologies to improve patient outcomes.

Support high-impact investigator-initiated research addressing ovarian cancer through basic laboratory to translational studies. Projects must demonstrate strong scientific rationale with preliminary data and potential to advance patient care.

The Army seeks research ideas to advance understanding and countermeasures for tick-borne diseases affecting military readiness. This program supports early-stage scientific investigations to develop novel prevention, diagnosis, or treatment solutions.

This DoD funding supports high-risk, hypothesis-driven research to discover new ALS drugs and therapies. Applications emphasizing novel approaches can succeed without preliminary data, enabling bold therapeutic innovation.

This DoD award supports clinical translational research to advance tuberous sclerosis complex diagnosis, prognosis, and treatments from promising preclinical findings toward real-world clinical application. Multi-PI teams can collaborate on moving TSC research closer to patient care.

This DoD program funds exploratory pancreatic cancer research with a patient-centered focus to develop innovative concepts and generate preliminary data for future clinical applications. Supported research should advance quality of life outcomes through robust studies that avoid preclinical animal work.

DoD seeks clinical trial research to advance treatment and management of military-relevant diseases. This peer-reviewed program funds trials from early-phase (Phase 0/1) through large-scale Phase 3 studies, with optional planning support for regulatory preparation.

The Army seeks innovative research on military burn treatment and prevention through discovery-phase awards. This funding targets novel solutions to improve clinical outcomes for service members with severe thermal injuries.

DoD seeks clinical research combining occupational science, psychology, and implementation science to address congressionally directed health topics. Projects must include patient advocates and demonstrate solutions to real-world health challenges.

Develop civilian nuclear infrastructure cooperation programs with Türkiye to advance nonproliferation security and safety standards. This initiative counters proliferation risks from non-U.S. reactor selection and foreign supply chains through targeted technical assistance.

This DoD program funds innovative research into tuberous sclerosis complex (TSC) to drive critical discoveries and improve patient care. It welcomes both established researchers and investigators new to the TSC field, with separate competitive tracks.

This DoD grant funds exploratory research into tuberous sclerosis complex treatments, welcoming high-risk, innovative concepts without requiring preliminary data. It supports early-stage hypothesis development to advance breakthrough therapeutic approaches.